Skip to main content
. 2019 Jun 19;2019:7641767. doi: 10.1155/2019/7641767

Table 2.

Advantages and disadvantages of srRNA- or mRNA-based reprogramming of fibroblasts to obtain footprint-free iPSCs.

srRNA reprogramming mRNA reprogramming
Advantages of srRNA
RNA generation No modified nucleotides Modified nucleotides
Identical RNA molecules Multiple mRNAs
RNA transfection Once (1 μg) Daily (1.2 μg) for 14-20 days
Transfection efficiency GFP reporter on the same srRNA construct Additional transfection with GFP mRNA for monitoring
First iPSCs emerged after 12 days 14 days
Reprogramming efficiency Very high efficiency after positive selection High efficiency (0.8%)
Reprogramming costs of RNA∗∗ ~2.5€ (1 μg srRNA once) ~60€ (~2.5€/1 μg mRNA for 20 days)
Transgene-free iPSCs Yes (total elimination of srRNA was demonstrated after p3) Yes (no integration of mRNA into the host genome)
Disadvantages of srRNA
RNA modification Posttranscriptional enzymatic 5′-capping and 3′-polyadenylation Cotranscriptional 5′-capping and 3′-polyadenylation
Immune system activation counteraction Interferon inhibitor B18R required∗∗∗ Interferon inhibitor B18R required∗∗∗
Transgene expression Check for residual srRNA expression (VEE virus-derived RNA construct) Natural degradation of mRNA in cells after 2-3 days

Modified nucleotides (e.g., 5mCTP, Pseudo-UTP, and N1-methylpseudo-UTP) can improve the translation of proteins but are also expensive to purchase. ∗∗Costs for the synthesis and purification of RNA (with commercially available kits, without plasmid generation) needed for one reprogramming experiment. ∗∗∗B18R-containing medium (BcM) can vary from batch to batch; therefore, the functionality of B18R has to be assessed before use, for example, by the determination of the positive transfection of fibroblasts with GFP mRNA with 25% BcM compared to the transfection without B18R. To date, there are no commercially available antibodies against B18R for specific analysis of the B18R content. For a constant quality, B18R can also be purchased as a recombinant protein, but this is much more expensive than the use of BcM.